

**PROPOSED AMENDMENTS TO
HOUSE BILL 2638**

1 On page 2 of the printed bill, delete lines 44 and 45 and delete pages 3
2 through 5 and insert:

3 **SECTION 2.** ORS 414.325 is amended to read:

4 “414.325. (1) As used in this section:

5 “(a) ‘Legend drug’ means any drug requiring a prescription by a practi-
6 tioner, as defined in ORS 689.005.

7 “(b) ‘Mental health drug’ means a type of legend drug defined by the
8 Oregon Health Authority by rule that includes, but is not limited to:

9 “(A) Therapeutic class 7 ataractics-tranquilizers; and

10 “(B) Therapeutic class 11 psychostimulants-antidepressants.

11 “(c) ‘Urgent medical condition’ means a medical condition that arises
12 suddenly, is not life-threatening and requires prompt treatment to avoid the
13 development of more serious medical problems.

14 “(2) The authority shall reimburse the cost of a legend drug prescribed
15 for a recipient of medical assistance only if the legend drug:

16 “(a) Is on the drug list of the Practitioner-Managed Prescription Drug
17 Plan adopted under ORS 414.334;

18 “(b) Is in a therapeutic class of nonsedating antihistamines and nasal
19 inhalers, as defined by the authority by rule, and is prescribed by an allergist
20 for the treatment of:

21 “(A) Asthma;

22 “(B) Sinusitis;

1 “(C) Rhinitis; or

2 “(D) Allergies; or

3 “(c) Is prescribed and dispensed under this chapter by a licensed practi-
4 tioner at a rural health clinic for an urgent medical condition and:

5 “(A) There is no pharmacy within 15 miles of the clinic;

6 “(B) The prescription is dispensed for a patient outside of the normal
7 business hours of any pharmacy within 15 miles of the clinic; or

8 “(C) No pharmacy within 15 miles of the clinic dispenses legend drugs
9 under this chapter.

10 “(3) The authority shall pay only for drugs in the generic form unless an
11 exception has been granted by the authority through the prior authorization
12 process adopted by the authority under subsection (4) of this section.

13 “(4) Notwithstanding subsection (2) of this section, the authority shall
14 provide reimbursement for a legend drug that does not meet the criteria in
15 subsection (2) of this section if:

16 “(a) It is a mental health drug.

17 “(b) The authority grants approval through a prior authorization process
18 adopted by the authority by rule.

19 “(c) The prescriber contacts the authority requesting prior authorization
20 and the authority or its agent fails to respond to the telephone call or to a
21 prescriber’s request made by electronic mail within 24 hours.

22 “(d) After consultation with the authority or its agent, the prescriber, in
23 the prescriber’s professional judgment, determines that the drug is medically
24 appropriate.

25 “(e) The original prescription was written prior to July 28, 2009, or the
26 request is for a refill of a prescription for:

27 “(A) The treatment of seizures, cancer, HIV or AIDS; or

28 “(B) An immunosuppressant.

29 “(f) It is a drug in a class not evaluated for the Practitioner-Managed
30 Prescription Drug Plan adopted under ORS 414.334.

1 “(5) Notwithstanding subsections (1) to (4) of this section, the authority
2 is authorized to:

3 “(a) Withhold payment for a legend drug when federal financial partic-
4 ipation is not available;

5 “(b) Require prior authorization of payment for drugs that the authority
6 has determined should be limited to those conditions generally recognized
7 as appropriate by the medical profession; *[and]*

8 “(c) Withhold payment for a legend drug that is not a funded health ser-
9 vice on the prioritized list of health services established by the Health Evi-
10 dence Review Commission under ORS *[414.720.]* **414.690; and**

11 **“(d) Require prior authorization, in accordance with 42 U.S.C.**
12 **1396r-8(d)(5), for a drug that:**

13 **“(A) Has not been evaluated by the Pharmacy and Therapeutics**
14 **Committee to determine if the drug has a meaningful therapeutic ad-**
15 **vantage in terms of safety, effectiveness or clinical outcomes; and**

16 **“(B) Is prescribed six months or less after the date the United**
17 **States Food and Drug Administration approved the drug for market-**
18 **ing.**

19 “(6) Notwithstanding ORS 414.334, the authority may conduct prospective
20 drug utilization review prior to payment for drugs for a patient whose pre-
21 scription drug use exceeded 15 drugs in the preceding six-month period.

22 “(7) Notwithstanding subsection (3) of this section, the authority may pay
23 a pharmacy for a particular brand name drug rather than the generic version
24 of the drug after notifying the pharmacy that the cost of the particular brand
25 name drug, after receiving discounted prices and rebates, is equal to or less
26 than the cost of the generic version of the drug.

27 “(8)(a) Within 180 days after the United States patent expires on an
28 immunosuppressant drug used in connection with an organ transplant, the
29 authority shall determine whether the drug is a narrow therapeutic index
30 drug.

1 “(b) As used in this subsection, ‘narrow therapeutic index drug’ means a
2 drug that has a narrow range in blood concentrations between efficacy and
3 toxicity and requires therapeutic drug concentration or pharmacodynamic
4 monitoring.

5 “(9) The authority shall appoint an advisory committee in accordance
6 with ORS 183.333 for any rulemaking conducted pursuant to this section.”.

7
